EXEL Stock DD Exelixis, Inc. Sunday, April 27, 2014 8:46:15

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
EXEL Exelixis, Inc. $EXEL Company Overview

Stock Message Board http://investorshangout.com/search?q=EXEL&...mp;yt1=Go!

Last Updated: Sunday, April 27, 2014 8:46:15 PM

Exelixis, Inc. EXEL Current Price and Quotes
Last Price 3.26
Previous Close 3.40 Open 3.35
Daily Range 3.26 - 3.39 52wk Range 3.02 - 8.41
Volume 3,051,982 Dividend N/A
Average Vol (3m) 5,124,102 Yield N/A
Exelixis, Inc. EXEL

Exelixis, Inc. EXEL
Exelixis, Inc. EXEL

Exelixis, Inc. EXEL


Exelixis, Inc. EXEL Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 31,338 47,450 289,636 185,045
Cost of Revenue 1,118 - - -
Gross Profit 30,220 47,450 289,636 185,045
Operating Expenses

Research and Development 178,763 128,878 156,836 210,678
Sales, General and Admin. 50,958 31,837 33,129 33,020
Non-Recurring Items 1,231 9,171 10,136 32,744
Other - - - -
Operating Income (200,732) (122,436) 89,535 (91,397)
Income From Continuing Operations

Add'l Income/Expense Items 1,223 1,986 3,716 8,335
Earnings Before Interest and Tax (199,509) (120,450) 93,251 (83,062)
Interest Expense 45,347 27,088 16,259 9,340
Earnings Before Tax (244,856) (147,538) 76,992 (92,402)
Income Tax (96) 107 1,295 (72)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (244,760) (147,645) 75,697 (92,330)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (244,760) (147,645) 75,697 (92,330)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (244,760) (147,645) 75,697 (92,330)

Exelixis, Inc. EXEL Recent News

Apr 21, 2014 Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014
Apr 4, 2014 European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer
Mar 25, 2014 Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer
Mar 25, 2014 Cometriq(R) approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. (Thomson Reu
Mar 25, 2014 Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Mar 24, 2014 Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
Feb 27, 2014 Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference
Feb 20, 2014 Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results
Feb 12, 2014 Exelixis Appoints Executive Vice President and General Counsel
Feb 10, 2014 Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call

1
2
next >

EXEL Exelixis, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=EXEL&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/EXEL/quote
Stock Chart http://www.otcmarkets.com/stock/EXEL/chart
Company Info http://www.otcmarkets.com/stock/EXEL/company-info
Recent News http://www.otcmarkets.com/stock/EXEL/news
Financials http://www.otcmarkets.com/stock/EXEL/financials
Filings and Disclosure http://www.otcmarkets.com/stock/EXEL/filings
Short Sales http://www.otcmarkets.com/stock/EXEL/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/EXEL/insider-transactions
Research Reports http://www.otcmarkets.com/stock/EXEL/research
Summary http://finance.yahoo.com/q?s=EXEL
Historical Prices http://finance.yahoo.com/q/hp?s=EXEL+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=EXEL
Basic Chart http://finance.yahoo.com/q/bc?s=EXEL+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=EXEL+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=EXEL+Headlines
Press Releases http://finance.yahoo.com/q/p?s=EXEL+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=EXEL+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=EXEL+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=EXEL+Industry
Major Holders http://finance.yahoo.com/q/mh?s=EXEL+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=EXEL+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=EXEL+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=EXEL
Balance Sheet http://finance.yahoo.com/q/bs?s=EXEL
Cash Flow http://finance.yahoo.com/q/cf?s=EXEL+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/EXEL
Market Watch http://www.marketwatch.com/investing/stock/EXEL
Bloomberg http://www.bloomberg.com/quote/EXEL:US
Morningstar http://quotes.morningstar.com/stock/s?t=EXEL
Bussinessweek http://investing.businessweek.com/research/st...icker=EXEL
Barchart http://www.barchart.com/quotes/stocks/EXEL
OTC Short Report http://otcshortreport.com/index.php?index=EXEL
Investopedia http://www.investopedia.com/markets/stocks/EXEL/?wa=0
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 3

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 2

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 7

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 4

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Discovering High-Yield Dividend Opportunities Today

Updated Category News Views 46

Ares Capital got traders buzzing back when it offered a solid yield of around 9%. It stood out as the largest publicly traded business development company (BDC) globally, which made income-focused investors take notice. But here’s the kicker: BDCs like Ares can sidestep corporate taxes if they hand out most of their earnings as dividends, creating a prime hunting ground...

Continue Reading
Anthony DiSilvestro Joins Keurig Dr Pepper as CFO

Updated Category News Views 175

Keurig Dr Pepper Welcomes New Chief Financial Officer Keurig Dr Pepper (NASDAQ: KDP) recently announced an exciting leadership change with the appointment of Anthony DiSilvestro as its new Chief Financial Officer. This important transition marks a significant step as DiSilvestro steps into his role immediately, bringing over four decades of extensive experience across...

Continue Reading
Elisa's New Branding: Introducing Elisa Industriq for Growth

Updated Category News Views 237

Elisa Unveils Elisa Industriq: A New Era in Software Solutions Elisa Oyj is excited to announce a significant milestone as it consolidates its international digital services under a unified brand known as Elisa Industriq. This initiative aims to streamline its software offerings and create a robust identity within the market. Following this change, Elisa will report the...

Continue Reading
Illinois American Water Backs United Way with Grants

Updated Category News Views 15

Driving Community Support Through Strategic Grants The American Water Charitable Foundation and Illinois American Water are making waves by putting their money where their mouth is, delivering a batch of state strategic impact grants to United Way organizations that promise to spark some serious change. It’s not every day you see such a duo diving into local communities...

Continue Reading
Essity Faces Early Bond Repayment Demand Amid Dispute

Updated Category News Views 43

Essity Faces Early Bond Repayment Demand Amid Dispute Essity has found itself in a challenging situation. Recently, a handful of bondholders have made a demand for the early repayment of bonds that are set to mature in the upcoming years of 2029, 2030, and 2031. This unexpected request has prompted Essity to reaffirm its position and contest the claims of these...

Continue Reading